Showing results (701-710 of 1,395) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|July 1, 2026
Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal CarcinomaHuaping Li, Qiuyu Jing, James Chung Hang Chow, et al.
JCO Precision Oncology|July 23, 2026
Revised Thyroid Differentiation Score for Risk Stratification in Papillary Thyroid CarcinomaVicente R Marczyk, Chia Chin Wu, Sarah Hamidi, et al.
JCO Precision Oncology|August 7, 2026
Identification of Predictive Biomarkers for Chemoradiotherapy Response in Rectal CancerMee-Na Park, Junho Kang, Jeong-Woo Hwang, et al.
JCO Precision Oncology|September 1, 2026
Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published CasesDaniel Dilg, Mike Blecker, Ana Vivancos, et al.
JCO Precision Oncology|September 1, 2026
Comparative Analysis of Potential Clinical Actionability of Genomic Alterations in Early-Onset Versus Later-Onset GI CancersLawrence W Wu, Jimyung Park, Sungjoo Jang, et al.
JCO Precision Oncology|November 25, 2021
Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid TumorsLieke M J van Zogchel, Nathalie S M Lak, Onno J H M Verhagen, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
JCO Precision Oncology|November 15, 2021
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort ExperienceJennifer J Gile, Fang-Shu Ou, Amit Mahipal, et al.
JCO Precision Oncology|November 15, 2021
Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryShumei Kato, Caroline Weipert, Sophia Gumas, et al.
Pageof 140